An interventional study of HIFT 1x/week and HIFT 2x/week in Metabolic Syndrome, Atherogenic Dyslipidemia and Insulin Resistance, sponsored by Gary Van Guilder. Completed at 1 site in United States. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Gary Van Guilder · Not applicable, Interventional, and Treatment
This study aims to explore the dose effects of three weekly volumes of high-intensity functional training (HIFT) on apolipoprotein B (ApoB), triglyceride (TG) and cholesterol (CHOL) content of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), and high-density lipoproteins (HDL) particles, fasting insulin and glucose, glycosylated hemoglobin (HbA1c), and endothelial function after a 12-week training program. Secondarily, this study aims to also explore the subjective dose-responses of "exercise enjoyment" and "intention to continue" after this 12-week training program.
Background: Individuals with metabolic syndrome (MetS) are at a greater risk for developing atherosclerotic cardiovascular disease (ASCVD) than those without MetS, due to underlying endothelial dysfunction, dyslipidemia, and insulin resistance. Exercise is an effective primary and secondary prevention strategy for MetS, however less than 25% of adults meet the minimum stated public recommendations. Barriers often identified are lack of enjoyment and lack of time. High intensity functional training (HIFT), a time efficient modality of exercise, has shown some potential to elicit positive affectivity, and elicit increased fitness and improved glucose metabolism. However, the effects of HIFT on dyslipidemia and endothelial dysfunction have not been explored, nor have the effects been explored in a population with MetS. Additionally, no studies have investigated the minimal dose of HIFT per week to see clinically meaningful changes in cardiometabolic health. The purpose of this study is to: 1) determine the dose-response effect of HIFT on blood lipids, insulin resistance, and endothelial function, and 2) determine the dose-response effect of HIFT on body composition, fitness, and perceived enjoyment and intention to continue the exercise.
Methods/design: In this randomized, dose-response trial, participants will undergo a 12-week HIFT intervention of either 1 day/week, 2 days/week, or 3 days/week of supervised, progressive exercise. Outcomes assessed at baseline and post-intervention will be multiple cardiometabolic markers, and fitness. Additionally, the participant's affective response will be measured after the intervention.
Discussion: The findings of this research will provide evidence on the minimal dose of HIFT per week to see clinically meaningful improvements in the risk factors of MetS, as well as whether this modality is likely to mitigate the barriers to exercise. If an effective dose of HIFT per week is determined and if this modality is perceived positively, it may provide exercise specialists and health care providers a tool to prevent and treat MetS.
1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.
This study's enrollment of 25 is below the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →Gary Van Guilder is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
HIFT exercise performed one time per week.
Behavioral: HIFT 1x/week
HIFT exercise performed two times per week.
Behavioral: HIFT 2x/week
HIFT exercise performed three times per week.
Behavioral: HIFT 3x/week
HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
Mean change from baseline and comparison between groups in apolipoprotein B (ApoB) count after 12 weeks of training.
Baseline and post-training blood analysis of apolipoprotein B will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the cholesterol content of low-density lipoproteins (LDL-C).
Baseline and post-training blood analysis of LDL-C will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the cholesterol content of very low-density lipoproteins (VLDL-C).
Baseline and post-training blood analysis of VLDL-C will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the cholesterol content of high-density lipoproteins (HDL-C).
Baseline and post-training blood analysis of HDL-C will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the total cholesterol (TC) content of all lipoproteins.
Baseline and post-training blood analysis of TC will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the triglyceride content of LDL (LDL-T).
Baseline and post-training blood analysis of LDL-T will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the triglyceride content of VLDL (VLDL-T).
Baseline and post-training blood analysis of VLDL-T will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the total triglyceride content of all lipoprotein classes (TG).
Baseline and post-training blood analysis of TG will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in blood glucose (BG).
Baseline and post-training blood analysis of BG will be measured via venipuncture of the anti-cubital vein and reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change for each variable will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in blood insulin (INS).
Baseline and post-training blood analysis of INS will be measured via venipuncture of the anti-cubital vein and reported in units of mcIU/mL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change for each variable will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in the Homeostatic Assessment of Insulin Resistance (HOMA-IR).
The baseline and post-training blood analysis of BG and INS will be used to calculate insulin resistance (IR) using the validated homeostatic model assessment (HOMA) \[Sarafidis et al., 2007; Matthews et al., 1985\]. HOMA-IR will be reported in units of mg/dL. Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change for each variable will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in glycosylated hemoglobin (HbA1c) after 12 weeks of training.
Baseline and post-training blood analysis of HbA1c will be measured via venipuncture of the anti-cubital vein and reported in units of percent (%). Change from baseline will be calculated and aggregated as mean (SD) for each dose group as well as for male and female subgroups within each dose group. The mean (SD) change for each variable will be compared between the three dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups of endothelial-dependent peak blood flow (PBF).
Baseline and post-training endothelial-dependent PBF of the non-dominant forearm will be measured using venous occlusion strain-gauge plethysmography and reported in units of percent (%). Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) for each variable will be compared between dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups of endothelial-dependent area under the curve (AUC) of hyperemia blood flow.
Baseline and post-training endothelial-dependent hyperemia AUC of the non-dominant forearm will be measured using venous occlusion strain-gauge plethysmography. Hyperemia blood flow will be measured for 5 min after a 5 min occlusion period. 30 sec AUC blood flow will be quantified reported in units of percent (%) x time. Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) for each variable will be compared between dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups of body fat mass percentage (FM%).
Baseline and post-training FM% will be measured via dual X-ray absorptiometry (DEXA) and reported as percentage of total body mass. Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male and female subgroups. Mean (SD) will be compared between dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups of body lean mass percentage (LM%).
Baseline and post-training LM% will be measured via dual X-ray absorptiometry (DEXA) and reported as percentage of total body mass. Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male and female subgroups. Mean (SD) will be compared between dose groups and male and female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups in maximal oxygen consumption (VO2max).
Baseline and post-training VO2max will be measured via a graded exercise test (GXT) on a power treadmill. After a 5 min warm-up, participants will walk at a constant speed while incline is increased 1% each minute until volitional exhaustion \[Balke \& Ware, 1959\] while VO2 is continuously captured. VO2max will be recorded and reported in units of mL/kg/min. Participants will rest passively for 20 min then perform a verification trial at 105% of their maximal GXT workload while VO2 is continuously captured until volitional exhaustion. If VO2max of the verification bout and GXT are within ± 3%, true VO2max will be considered achieved \[Astorino et al., 2009; Nolan et al., 2014; Weatherwax et al., 2016\]. If verification is not achieved, they will repeat the trial after a 24hr rest. Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) will be compared between the three dose groups and male/female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Mean change from baseline and comparison between groups of self-perceived fitness after 12 weeks of training.
Baseline and post-training self-perceived fitness will be measured using the validated International Fitness Scale (IFIS) \[Ortega et al., 2011; Merellano-Navarro et al., 2017\] and reported as the sum of all scores. The scale contains five questions with the answering options (Very Poor-1, Poor-2, Average-3, Good-4, Very Good-5) associated to these elements of physical fitness: cardiorespiratory endurance, muscular strength, speed-agility, and flexibility. Change from baseline will be calculated and aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) will be compared between the three dose groups and male/female subgroups.
Time frame: Baseline and 48hrs post 12-week training completion
Comparison between groups of exercise enjoyment perception after 12 weeks of training.
To assess the participants perception of enjoyment of their allocated HIFT intervention, the validated Physical Activity Enjoyment Scale (PACES) will be used \[Kendzierski \& DeCarlo, 1991\] and reported as the sum of all scores. The PACES is an 18-item, 7-point bipolar rating scale where 1 represents the lowest level of enjoyment and 7 represents the highest level of enjoyment. Data will be aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) will be compared between dose groups and male/female subgroups.
Time frame: 24hrs post 12-week training completion
Comparison between groups of the intention to continue their allocated intervention after 12 weeks of training.
To assess the participants intention to continue their allocated HIFT intervention, two additional items will be added to the PACES regarding 1) how likely the participant will continue performing the modality of exercise (0=unlikely to 10=very likely) and 2) how many days per week the participant will would consider performing the modality of exercise (0-7 days) \[Kwan \& Bryan, 2010; Heinrich et al., 2019\]. Data per question will be aggregated as mean (SD) for each dose group and male/female subgroups. Mean (SD) will be compared between dose groups and male/female subgroups.
Time frame: 24hrs post 12-week training completion
Plan to share: Yes — De-identified IPD will be available upon request.
Supporting information: Study protocol, Sap, Csr
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gary Van Guilder